Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Evaluate the efficacy of Abraxane in first line chemotherapy of patients with hormone
refractory metastatic prostate cancer, based on prostate specific antigen (PSA) response